WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $65 | $110 | $206 | $339 |
| - Cash | $8 | $10 | $6 | $9 |
| + Debt | $5 | $5 | $4 | $4 |
| Enterprise Value | $61 | $105 | $204 | $335 |
| Revenue | $19 | $17 | $15 | $10 |
| % Growth | 9.6% | 11.6% | 48.4% | – |
| Gross Profit | $8 | $7 | $7 | $5 |
| % Margin | 41% | 40.1% | 44% | 46.9% |
| EBITDA | $6 | $6 | $6 | $5 |
| % Margin | 34.4% | 32.3% | 40.8% | 43.9% |
| Net Income | $3 | $3 | $4 | $3 |
| % Margin | 18% | 20% | 29% | 32.9% |
| EPS Diluted | 0.78 | 0.77 | 1.01 | 0.77 |
| % Growth | 1.3% | -23.8% | 31.2% | – |
| Operating Cash Flow | $5 | $5 | $6 | $3 |
| Capital Expenditures | -$4 | -$4 | -$6 | -$7 |
| Free Cash Flow | $1 | $0 | -$0 | -$3 |